CTLA4 and breast carcinoma: CTLA-4 mAB’s has suboptimal antitumor activity and high toxicity effect of anti-CTLA-4 monotherapy in BC; thus, anti-CTLA-4 combination therapy is being explored as an alternative for breast cancer [57].